Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration

The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate. To assess the impact of HIV-1 subtype and antiretroviral treatment on...

Full description

Saved in:
Bibliographic Details
Published in:PLoS medicine 2005-04, Vol.2 (4), p.e112-e112
Main Authors: Kantor, Rami, Katzenstein, David A, Efron, Brad, Carvalho, Ana Patricia, Wynhoven, Brian, Cane, Patricia, Clarke, John, Sirivichayakul, Sunee, Soares, Marcelo A, Snoeck, Joke, Pillay, Candice, Rudich, Hagit, Rodrigues, Rosangela, Holguin, Africa, Ariyoshi, Koya, Bouzas, Maria Belen, Cahn, Pedro, Sugiura, Wataru, Soriano, Vincent, Brigido, Luis F, Grossman, Zehava, Morris, Lynn, Vandamme, Anne-Mieke, Tanuri, Amilcar, Phanuphak, Praphan, Weber, Jonathan N, Pillay, Deenan, Harrigan, P Richard, Camacho, Ricardo, Schapiro, Jonathan M, Shafer, Robert W
Format: Article
Language:English
Subjects:
Amino Acid Sequence
Anti-Retroviral Agents - pharmacology
Anti-Retroviral Agents - therapeutic use
Antiretroviral drugs
Collaboration
DNA Mutational Analysis
Drug resistance
Drug Resistance, Viral
Drug therapy
Global Health
HIV
HIV Infection/AIDS
HIV Infections - drug therapy
HIV-1 - classification
HIV-1 - genetics
HIV-1 - pathogenicity
HIV/AIDS
Human immunodeficiency virus
Humans
Infectious Diseases
Laboratories
Molecular Sequence Data
Mutation
Pandemics
Peptide Hydrolases - genetics
RNA-Directed DNA Polymerase - genetics
Surveillance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate. To assess the impact of HIV-1 subtype and antiretroviral treatment on the distribution of mutations in protease and reverse transcriptase, a binomial response model using subtype and treatment as explanatory variables was used to analyze a large compiled dataset of non-subtype-B HIV-1 sequences. Non-subtype-B sequences from 3,686 persons with well characterized antiretroviral treatment histories were analyzed in comparison to subtype B sequences from 4,769 persons. The non-subtype-B sequences included 461 with subtype A, 1,185 with C, 331 with D, 245 with F, 293 with G, 513 with CRF01_AE, and 618 with CRF02_AG. Each of the 55 known subtype B drug-resistance mutations occurred in at least one non-B isolate, and 44 (80%) of these mutations were significantly associated with antiretroviral treatment in at least one non-B subtype. Conversely, of 67 mutations found to be associated with antiretroviral therapy in at least one non-B subtype, 61 were also associated with antiretroviral therapy in subtype B isolates. Global surveillance and genotypic assessment of drug resistance should focus primarily on the known subtype B drug-resistance mutations.
ISSN:1549-1676
1549-1277
1549-1676
DOI:10.1371/journal.pmed.0020112